Advertisement

Topics

BlackThorn Therapeutics to Receive Up to $8 Million in NIH Blueprint Neurotherapeutics Network Funding to Advance Kappa Opioid Receptor (KOR) Antagonist Program

09:00 EDT 20 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
BlackThorn Therapeutics, a clinical-stage biopharmaceutical company discovering and developing targeted treatments for neurobehavioral disorders, today announced it has received a grant from the National Institute of Neurologica...

Other Sources for this Article

Pure Communications
Julie Normart, 415-946-1087
jnormart@purecommunications.com

NEXT ARTICLE

More From BioPortfolio on "BlackThorn Therapeutics to Receive Up to $8 Million in NIH Blueprint Neurotherapeutics Network Funding to Advance Kappa Opioid Receptor (KOR) Antagonist Program"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Stroke - Cerebrovascular Disease (CVA)
A stroke is a serious medical condition that occurs when the blood supply to part of the brain is cut off. Strokes are a medical emergency and prompt treatment is essential because the sooner a person receives treatment for a stroke, the less damage is ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...